A Phase 2 interventional study of Somatropin and Control Arm in Growth Hormone Therapy and Infant, Very Low Birth Weight, sponsored by Pfizer. Completed at 8 sites in Germany. Open to participants aged 4 Years to 10 Years. Per ClinicalTrials.gov, last updated 2017-04-05.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Safety and efficacy of Somatropin will be evaluated in short children born with a list weight below 1500 g and that did not catch up to normal height at the age of 4.
185 studies on the registry are indexed under Birth Weight; 24 are open to participants now.
This study's enrollment of 33 is below the median of 170 across 117 interventional studies indexed under Birth Weight.
Browse Birth Weight studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
Exclusion Criteria:
Subjects presenting with any of the following will not be included in the trial:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Somatropin · Other: Control Arm
Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. Children randomized to the control group will get the possibility to continue treatment for a further year. The study will end after 2 and 3 years of observation, respectively.
Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. The study will end after 2 and 3 years of observation, respectively. Children randomized to the control group will get the possibility to continue treatment for a further year.
Change in Height Standard Deviation Score (SDS) After 1 Year
Change in Height SDS after 1 year where SDS=height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).
Time frame: Baseline to 1 year (Month 12)
Change in Growth Velocity Standard Deviation Score (SDS) After 1 Year
Change in Growth Velocity (GV) SDS after 1 year where SDS=GV minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).
Time frame: Baseline to 1 year (Month 12)
Change From Baseline in Growth Velocity After 1 Year and After 2 Years
Growth velocity measured as centimeters per year.
Time frame: Baseline, Month 12, Month 24
Change From Baseline in Growth Velocity SDS After 2 Years
Change in Growth Velocity SDS after 2 years (24 months) where SDS = growth velocity minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).
Time frame: Baseline, Month 24
Change From Baseline in Height After 1 Year and After 2 Years
Time frame: Baseline, Month 12, Month 24
Change From Baseline in Height SDS After 2 Years
Change in Height SDS after 2 years (24 months) where SDS = height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).
Time frame: Baseline, Month 24
Change From Baseline in Body Composition (Skinfold Thickness) After 1 Year and After 2 Years: Triceps
Body composition measured as skinfold thickness at tricep in millimeters (mm); measured halfway down the left upper arm with arm hanging in relaxed position at participant's side.
Time frame: Baseline, Month 12, Month 24
Change From Baseline in Body Composition (Skinfold Thickness) After 1 Year and After 2 Years: Subscapular
Body composition measured as subscapular skinfold thickness in millimeters (mm); measured laterally just below the angle of the left scapula.
Time frame: Baseline, Month 12, Month 24
Change From Baseline in Body Composition (Skinfold Thickness) After 1 Year and After 2 Years: Suprailiac
Body composition measured as suprailiac skinfold thickness in millimeters (mm); measured just above the iliac crest in the middle-axillary line.
Time frame: Baseline, Month 12, Month 24
Change From Baseline in Volumetric Cortical Bone Mineral Density (BMD) Using Peripheral Quantitative Computed Tomography (pQCT) After 1 Year and After 2 Years
Volumetric Cortical BMD measured as milligrams per cubic millimeter (mg/mm3). BMD (proximal radius) SDS (number of standard deviations a participant's BMD differs from the average BMD of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
Time frame: Baseline, Month 12, Month 24
Change From Baseline in Bone Structure Using pQCT After 1 Year and 2 Years: Cortical Cross-sectional Area (CSA)
Bone structure Cortical CSA measured as millimeters squared (mm2). CSA (proximal radius) SDS (number of standard deviations a participant's CSA differs from the average CSA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
Time frame: Baseline, Month 12, Month 24
Change From Baseline in Bone Structure Using Peripheral Quantitative Computed Tomography (pQCT) After 1 Year and 2 Years: Total Cross-sectional Area (CSA)
Bone structure Total CSA measured as millimeters squared (mm2). Total CSA (proximal radius) SDS (number of standard deviations a participant's CSA differs from the average CSA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
Time frame: Baseline, Month 12, Month 24
Change From Baseline in Bone Structure Using pQCT After 1 Year and 2 Years: Muscle Cross-sectional Area (CSA)
Bone structure Muscle CSA measured as millimeters squared (mm2). CSA (proximal radius) SDS (number of standard deviations a participant's CSA differs from the average CSA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
Time frame: Baseline, Month 12, Month 24
Change From Baseline in Bone Structure Using pQCT After 1 Year and 2 Years: Cortical Thickness (CT)
Cortical Thickness measured as millimeters (mm). CT (proximal radius) SDS (number of standard deviations a participant's CT differs from the average CT of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
Time frame: Baseline, Month 12, Month 24
Change From Baseline in Bone Structure Using pQCT After 1 Year and 2 Years: Marrow Area (MA)
Marrow Area measured as millimeters squared (mm2). MA (proximal radius) SDS (number of standard deviations a participant's MA differs from the average MA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
Time frame: Baseline, Month 12, Month 24
Change From Baseline in Bone Stability Using pQCT After 1 Year and After 2 Years: Strength-strain Index (SSI)
Bone stability expressed as polar SSI in cubic millimeters (mm3). SSI (proximal radius) SDS (number of standard deviations a participant's SSI differs from the average SSI of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
Time frame: Baseline, Month 12, Month 24
Change From Baseline in Muscle Strength: Hand Grip SDS After 1 Year and After 2 Years
Muscle strength determined by measuring grip force (kilograms) using hand grip dynamometer for participants ≥6 years of age. Baseline and post-baseline SDS values transformed to age and sex specific z-score. Change in hand grip calculated as SDS where SDS = hand grip minus mean (age- and sex-matched reference) divided by SD (age- and sex-matched reference). Positive values are above the average for participant's age and sex; negative values are below the average.
Time frame: Baseline, Month 12, Month 24
Number of Participants With Change in Insulin Sensitivity: Somatropin
Insulin sensitivity calculated as incidence of pathological glucose intolerance assessed prior to randomization (Screening Day -3 to Baseline Day 0) and at final visit (final visit: Somatropin treatment group=Month 24). Pathological glucose intolerance (oral glucose tolerance test) measured as venous (blood or plasma) with range minimum 120 milligrams per deciliter (mg/dL) to \>140 mg/dL; capillary (blood) with range minimum 120 mg/dL to \>120 mg/dL; or method not known with range minimum 120 mg/dL to \>120 mg/dL.
Time frame: Baseline, Month 24
Number of Participants With Change in Insulin Sensitivity: Control Arm
Insulin sensitivity calculated as incidence of pathological glucose intolerance assessed prior to randomization (Screening Day -3 to Baseline Day 0) and at final visit (final visit: Control Arm=Month 36). Pathological glucose intolerance (oral glucose tolerance test) measured as venous (blood or plasma) with range minimum 120 milligrams per deciliter (mg/dL) to \>140 mg/dL; capillary (blood) with range minimum 120 mg/dL to \>120 mg/dL; or method not known with range minimum 120 mg/dL to \>120 mg/dL.
Time frame: Baseline, Month 36
Growth Curve Comparison Based on Height SDS
Growth curve comparison with height SDS in centimeters as the dependent variable; SDS = height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).
Time frame: Month 12, Month 24
Growth Curve Comparison Based on Height SDS: Control Arm
Growth curve comparison with height SDS in centimeters as the dependent variable; SDS = height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference). Control Arm final visit=Month 36.
Time frame: Month 36
Growth Curve Comparison Based on Height
Growth curve comparison with height in centimeters as the dependent variable.
Time frame: Month 12, Month 24
Growth Curve Comparison Based on Height: Control Arm
Growth curve comparison with height in centimeters as the dependent variable.
Time frame: Month 36
| Milestone | Somatropin | Control Arm |
|---|---|---|
| Started | 18 | 15 |
| Received study treatment | 18 | 14 |
| Completed | 18 | 14 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Change in Height SDS after 1 year where SDS=height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).
| centimeters | Somatropin | Control Arm |
|---|---|---|
| Change in Height Standard Deviation Score (SDS) After 1 Year | 1.099 ± 0.0714 | 0.108 ± 0.0783 |
Growth velocity measured as centimeters per year.
| centimeters per year | Somatropin | Control Arm |
|---|---|---|
| Month 12 | 5.110 ± 0.2623 | 0.695 ± 0.2881 |
| Month 24 | 3.049 ± 0.3546 | 3.934 ± 0.3893 |
Change in Growth Velocity SDS after 2 years (24 months) where SDS = growth velocity minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).
| centimeters per year | Somatropin | Control Arm |
|---|---|---|
| Change From Baseline in Growth Velocity SDS After 2 Years | 4.751 ± 0.4716 | 5.825 ± 0.5177 |
| centimeters | Somatropin | Control Arm |
|---|---|---|
| Month 12 | 10.467 ± 0.2439 | 5.927 ± 0.2677 |
| Month 24 | 18.908 ± 0.6507 | 14.844 ± 0.7149 |
Change in Height SDS after 2 years (24 months) where SDS = height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).
| centimeters | Somatropin | Control Arm |
|---|---|---|
| Change From Baseline in Height SDS After 2 Years | 1.710 ± 0.1075 | 0.991 ± 0.1179 |
Body composition measured as skinfold thickness at tricep in millimeters (mm); measured halfway down the left upper arm with arm hanging in relaxed position at participant's side.
| millimeters | Somatropin | Control Arm |
|---|---|---|
| Month 12 | -2.20 ± 0.341 | 0.50 ± 0.353 |
| Month 24 | -1.30 ± 0.511 | -0.83 ± 0.548 |
Body composition measured as subscapular skinfold thickness in millimeters (mm); measured laterally just below the angle of the left scapula.
| millimeters | Somatropin | Control Arm |
|---|---|---|
| Month 12 | 0.08 ± 0.276 | 0.46 ± 0.286 |
| Month 24 | 0.27 ± 0.231 | 0.50 ± 0.247 |
Body composition measured as suprailiac skinfold thickness in millimeters (mm); measured just above the iliac crest in the middle-axillary line.
| millimeters | Somatropin | Control Arm |
|---|---|---|
| Month 12 | 0.51 ± 0.783 | 0.45 ± 0.849 |
| Month 24 | 0.90 ± 0.688 | 0.79 ± 0.774 |
Volumetric Cortical BMD measured as milligrams per cubic millimeter (mg/mm3). BMD (proximal radius) SDS (number of standard deviations a participant's BMD differs from the average BMD of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
| z-score | Somatropin | Control Arm |
|---|---|---|
| Month 12 (n=2, 6) | -1.055 ± 0.6802 | -0.162 ± 0.3600 |
| Month 24 (n=2, 6) | 0.284 ± 0.5023 | -0.433 ± 0.2658 |
Change in Growth Velocity (GV) SDS after 1 year where SDS=GV minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).
| centimeters per year | Somatropin | Control Arm |
|---|---|---|
| Change in Growth Velocity Standard Deviation Score (SDS) After 1 Year | 7.117 ± 0.4384 | 1.502 ± 0.4814 |
Bone structure Cortical CSA measured as millimeters squared (mm2). CSA (proximal radius) SDS (number of standard deviations a participant's CSA differs from the average CSA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
| z-score | Somatropin | Control Arm |
|---|---|---|
| Month 12 (n=2, 5) | -0.465 ± 0.7799 | 0.017 ± 0.4559 |
| Month 24 (n=2, 6) | -0.595 ± 0.7462 | 0.609 ± 0.3907 |
Bone structure Total CSA measured as millimeters squared (mm2). Total CSA (proximal radius) SDS (number of standard deviations a participant's CSA differs from the average CSA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
| z-score | Somatropin | Control Arm |
|---|---|---|
| Month 12 (n=2, 5) | 0.375 ± 0.9345 | 0.239 ± 0.5537 |
| Month 24 (n=2, 6) | 0.243 ± 0.3694 | -0.049 ± 0.1955 |
Bone structure Muscle CSA measured as millimeters squared (mm2). CSA (proximal radius) SDS (number of standard deviations a participant's CSA differs from the average CSA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
| z-score | Somatropin | Control Arm |
|---|---|---|
| Month 12 (n=2, 6) | 2.084 ± 0.3628 | -0.227 ± 0.1688 |
| Month 24 (n=2, 6) | 2.402 ± 0.5221 | 0.776 ± 0.2428 |
Cortical Thickness measured as millimeters (mm). CT (proximal radius) SDS (number of standard deviations a participant's CT differs from the average CT of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
No measurements were reported for this outcome.
Marrow Area measured as millimeters squared (mm2). MA (proximal radius) SDS (number of standard deviations a participant's MA differs from the average MA of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
No measurements were reported for this outcome.
Bone stability expressed as polar SSI in cubic millimeters (mm3). SSI (proximal radius) SDS (number of standard deviations a participant's SSI differs from the average SSI of their age and sex). Baseline and post-baseline SDS values transformed to age and sex specific z-score (Ln(test result/M)\]/S); Ln=natural logarithm; M=age- or height-) and sex-specific mean value; S=age-(or height-) and sex-specific coefficient of variation) then change from baseline is calculated. Positive values are above the average for participant's age and sex; negative values are below the average.
| z-score | Somatropin | Control Arm |
|---|---|---|
| Month 12 (n=2, 6) | 0.648 ± 0.4224 | 0.088 ± 0.2243 |
| Month 24 (n=2, 6) | 0.477 ± 0.3925 | 0.363 ± 0.2084 |
Muscle strength determined by measuring grip force (kilograms) using hand grip dynamometer for participants ≥6 years of age. Baseline and post-baseline SDS values transformed to age and sex specific z-score. Change in hand grip calculated as SDS where SDS = hand grip minus mean (age- and sex-matched reference) divided by SD (age- and sex-matched reference). Positive values are above the average for participant's age and sex; negative values are below the average.
| z-score | Somatropin | Control Arm |
|---|---|---|
| Month 12 (n=7, 5) | 0.37 ± 0.268 | 0.28 ± 0.318 |
| Month 24 (n=7, 6) | 1.14 ± 0.218 | 0.92 ± 0.236 |
Insulin sensitivity calculated as incidence of pathological glucose intolerance assessed prior to randomization (Screening Day -3 to Baseline Day 0) and at final visit (final visit: Somatropin treatment group=Month 24). Pathological glucose intolerance (oral glucose tolerance test) measured as venous (blood or plasma) with range minimum 120 milligrams per deciliter (mg/dL) to \>140 mg/dL; capillary (blood) with range minimum 120 mg/dL to \>120 mg/dL; or method not known with range minimum 120 mg/dL to \>120 mg/dL.
| participants | Somatropin |
|---|---|
| Baseline: tolerant | 18 |
| Baseline: intolerant | 0 |
| Month 24: tolerant | 16 |
| Month 24: intolerant | 0 |
Insulin sensitivity calculated as incidence of pathological glucose intolerance assessed prior to randomization (Screening Day -3 to Baseline Day 0) and at final visit (final visit: Control Arm=Month 36). Pathological glucose intolerance (oral glucose tolerance test) measured as venous (blood or plasma) with range minimum 120 milligrams per deciliter (mg/dL) to \>140 mg/dL; capillary (blood) with range minimum 120 mg/dL to \>120 mg/dL; or method not known with range minimum 120 mg/dL to \>120 mg/dL.
| participants | Control Arm |
|---|---|
| Baseline: tolerant | 14 |
| Baseline: intolerant | 1 |
| Month 36: tolerant | 11 |
| Month 36: intolerant | 2 |
Growth curve comparison with height SDS in centimeters as the dependent variable; SDS = height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference).
| centimeters | Somatropin | Control Arm |
|---|---|---|
| Month 12 | -2.260 ± 0.0735 | -3.259 ± 0.0802 |
| Month 24 | -1.638 ± 0.1016 | -2.327 ± 0.1122 |
Growth curve comparison with height SDS in centimeters as the dependent variable; SDS = height minus mean (age-and sex-matched reference) divided by SD (age and sex-matched reference). Control Arm final visit=Month 36.
| centimeters | Control Arm |
|---|---|
| Growth Curve Comparison Based on Height SDS: Control Arm | -1.794 ± 0.1318 |
Growth curve comparison with height in centimeters as the dependent variable.
| centimeters | Somatropin | Control Arm |
|---|---|---|
| Month 12 | 114.228 ± 0.3330 | 109.644 ± 0.3733 |
| Month 24 | 123.351 ± 0.4830 | 119.788 ± 0.5255 |
Growth curve comparison with height in centimeters as the dependent variable.
| centimeters | Control Arm |
|---|---|
| Growth Curve Comparison Based on Height: Control Arm | 128.049 ± 0.7821 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Somatropin | — | 5/18 (27.8%) | 13/18 (72.2%) |
| Control Arm | — | 1/15 (6.7%) | 11/15 (73.3%) |
| Event | Somatropin | Control Arm |
|---|---|---|
| TonsillitisInfections and infestations | 2/18 | 0/15 |
| Facial palsyNervous system disorders | 0/18 | 1/15 |
| PyrexiaGeneral disorders | 1/18 | 0/15 |
| Acute tonsillitisInfections and infestations | 1/18 | 0/15 |
| Bronchitis viralInfections and infestations | 1/18 | 0/15 |
| BronchopneumoniaInfections and infestations | 1/18 | 0/15 |
| Ear infectionInfections and infestations | 1/18 | 0/15 |
| Febrile convulsionNervous system disorders | 1/18 | 0/15 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/18 | 0/15 |
| Event | Somatropin | Control Arm |
|---|---|---|
| TonsillitisInfections and infestations | 4/18 | 1/15 |
| Acute tonsillitisInfections and infestations | 1/18 | 2/15 |
| BronchitisInfections and infestations | 1/18 | 2/15 |
| NasopharyngitisInfections and infestations | 2/18 | 2/15 |
| RhinitisInfections and infestations | 2/18 | 2/15 |
| Upper respiratory tract infectionInfections and infestations | 2/18 | 2/15 |
| Febrile infectionInfections and infestations | 2/18 | 0/15 |
| Attention deficit / hyperactivity disorderPsychiatric disorders | 2/18 | 0/15 |
| Autoimmune thyroiditisEndocrine disorders | 0/18 | 1/15 |
| HypothyroidismEndocrine disorders | 1/18 | 1/15 |
| Age, Continuous(years) | Somatropin | Control Arm | Total |
|---|---|---|---|
| Mean | 5.4 ± 1.6 | 5.7 ± 1.9 | 5.5 ± 1.7 |
| Age, Customized(Participants) | Somatropin | Control Arm | Total |
|---|---|---|---|
| <4 years | 1 ± 1.5 | 1 ± 1.9 | 2 ± 1.7 |
| ≥4 years and <8 years | 14 | 11 | 25 |
| ≥8 years and <12 years | 3 | 3 | 6 |
| Sex: Female, Male(Participants) | Somatropin | Control Arm | Total |
|---|---|---|---|
| Female | 9 | 7 | 16 |
| Male | 9 | 8 | 17 |
The record gives a start of Aug 2005, a primary completion of Mar 2008 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone